Oral and injectable incretin modalities, such as GLP-1 agonists are critical to address the high unmet need in the obesity market, Roche said in its press release
In addition to their effects on glycaemic control, some of these medications are indicated for weight management and are therefore gaining popularity
GLP-1 medications have reshaped the way we understand obesity not as a lack of willpower but as a complex, chronic condition
10.3389/fmed.2023.1187163 99 KrugerA.VlokM.TurnerS.VenterC.LaubscherG
But Eimer emphasized that the findings should not discourage appropriate use of GLP-1 drugs, which have become increasingly popular for treating diabetes, obesity, cardiovascular disease and sleep apnea
The approval significantly expanded the commercial opportunity for GLP-1-based obesity therapies and intensified competition with Wegovy in the rapidly growing anti-obesity drug market In March 2024, Novo Nordisk secured U.S
